
Loading, please wait...

Loading, please wait...

Recent data highlights a significant surge in tobacco consumption in India between 2011 and 2024. Consequently, the Economic Advisory Council to the Prime Minister (EAC-PM) has released a working paper calling for urgent policy interventions. This trend poses serious risks to both individual health and the long-term sustainability of public finances. Therefore, authorities must act now to curb this growing epidemic.
Tobacco use remains a primary driver of non-communicable diseases (NCDs) nationwide. Specifically, the Ministry of Health attributes approximately 13 lakh annual deaths to tobacco-related complications. These include cardiovascular diseases, respiratory illnesses, and various cancers. Furthermore, the rising incidence of tobacco use among poorer households places an immense strain on the state’s healthcare budget. Schemes like Ayushman Bharat bear the brunt of these preventable chronic conditions. Thus, addressing consumption is vital for safeguarding the nation's human capital.
The EAC-PM suggests a multi-pronged strategy to reduce consumption levels effectively. First, the paper recommends rationalizing and strengthening taxation across all tobacco products. While a 100% levy on chewing tobacco is a strong step, fiscal measures alone may not suffice. Second, the government should tighten enforcement against illicit and surrogate sales. Moreover, integrating preventive counseling within primary healthcare systems can provide crucial support for those wishing to quit. By expanding awareness campaigns, the state can better protect vulnerable populations from addictive products.
Q1: Which tobacco products are most popular in urban Indian households?
Cigarettes are the most common tobacco product in cities, used by 18.1% of urban households. Gutkha follows closely, with a 16.8% usage rate among city dwellers.
Q2: How much has tobacco expenditure increased in recent years?
Per capita spending on tobacco rose sharply by 58% in rural India and 77% in urban areas between 2011-12 and 2023-24.
Q3: What are the main recommendations of the EAC-PM working paper?
The paper suggests rationalizing tobacco taxes, tightening enforcement against illicit sales, expanding awareness campaigns, and integrating preventive counseling in primary care.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


EAC-PM warns of rising tobacco consumption in India, urging higher taxes and healthcare integration to protect public health and fiscal sustainability....
5 months ago

Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today

A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday

A comprehensive meta-analysis shows digital health technologies significantly improve 6-minute walk distance and peak oxygen uptake in chronic heart failure patients, highlighting the clinical promise of structured remote cardiac rehabilitation.
Today

Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today

A comprehensive analysis of continuous glucose monitoring systems under European Medical Device Regulation 2017/745, examining conformity assessment challenges, Notified Body backlogs, EUDAMED rollout delays, and the critical need for transparent post-market surveillance.
Today